Tag:
Theravance
Latest Headlines
Latest Headlines
UPDATED: GSK, Theravance share mixed bag of lung drug data ahead of FDA filing
GlaxoSmithKline and Theravance have dropped another up-and-down set of data related to development of their blockbuster hopeful Relovair.
GSK will cut 3 R&D units, add 4 as DPU review triggers shakeup
Following a three-year review of its new approach to R&D, GlaxoSmithKline ( $GSK ) today revealed that it has decided to ax three of its 38 tightly-focused research units and add four more in a
PhRMA's COPD pipeline report spotlights blockbuster hopefuls
Anyone looking for a basic primer on experimental COPD drugs should check out PhRMA's latest compilation of new drugs in the pipeline. The big trade group found 54 COPD studies underway, which
Astellas dumps Theravance's MRSA drug Vibativ
Astellas Pharma parted ways with Theravance ($THRX), ending a promotional partnership on the infection-fighter Vibativ. FDA-approved in 2009, the drug targets infections caused by resistant staph
Theravance shares tank on troubling study results for Relovair
by Suzanne Elvidge and John Carroll Shares of GlaxoSmithKline ( $GSK ) caught a chill this morning after investigators released mixed late-stage data and flagged troubling safety concerns for its COPD
GSK, Theravance report Ph3 successes for COPD treatment
GlaxoSmithKline and Theravance are giving analysts a thumbs-up on their late-stage studies of Relovair, the next-gen COPD successor to Advair. Investigators say that the drug bested a placebo in the
GSK boosts Theravance stake after grabbing lead in drug race
GlaxoSmithKline is putting some added financial muscle into its embrace of South San Francisco-based Theravance. The pharma giant is investing close to $130 million to boost its stake in its biotech
GSK claims lead in Ph3 respiratory drug race
Novartis says that its closely watched asthma and COPD drug QMF149 will be delayed, pushing back a planned filing to 2014. And that means that GSK's next-gen respiratory drug may well get to the
GSK, Theravance report promising PhII data for Advair successor
GlaxoSmithKline and partner Theravance (THRX) say that their planned successor for the blockbuster Advair turned in a positive performance in a mid-stage study involving 60 people with COPD.
FDA wants more studies of Vibativ for pneumonia
The FDA wants more data on Theravance's Vibativ (telavancin) before it will approve the treatment for nosocomial pneumonia. The agency suggested a design for any new trials, which means getting the
